Trial Profile
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy and in Combination With Chemotherapy and/or Immunotherapy in Subjects With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and Locoregional Gastric or GEJ Adenocarcinoma Whose Are Claudin (CLDN) 18.2 Positive
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Nivolumab (Primary) ; Oxaliplatin (Primary) ; Pembrolizumab (Primary) ; Zolbetuximab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms ILUSTRO
- Sponsors Astellas Pharma Global Development
- 20 Dec 2023 Docetaxel has bene added in the study, hence number of treatment arms has been changed to 5.
- 31 Oct 2023 Planned number of patients changed from 116 to 143.
- 31 Oct 2023 Planned End Date changed from 31 Jul 2024 to 31 Dec 2026.